



October 28, 2021  
JCR Pharmaceuticals Co., Ltd.

Translation

**Notice of Distribution of Retained Earnings (Increase in Interim Dividend) and  
Revision of Year-End Dividend Forecast (Increase in Dividend)**

Oct. 28 -- JCR Pharmaceuticals Co., Ltd. (TSE: 4552; Chairman and President: Shin Ashida; "JCR") announced that its Board of Directors resolved at a meeting held today to distribute retained earnings (increase in interim dividend) with the record date being September 30, 2021, as described below, and to revise its forecast of the year-end dividend (increase in dividend) with the record date being March 31, 2022.

1. Details of interim dividend

	Amount decided	Latest forecast for dividend (Released on May 13, 2021)	Actual result for previous interim period (Six months ended September 30, 2020)
Record date	September 30, 2021	September 30, 2021	September 30, 2020
Dividend per share	10.00 yen	8.00 yen	18.00 yen*
Total amount of dividend	1,241 million yen	—	557 million yen
Effective date	December 10, 2021	—	December 10, 2020
Dividend resource	Retained earnings	—	Retained earnings

\*JCR conducted a four-for-one stock split of its common stock on October 1, 2020. Since the record date for its interim dividend is September 30 as stated above, dividend per share for the six months ended September 30, 2020 represents the figure before the stock split. The dividend per share after considering the stock split would be 4.50 yen.

2. Details of year-end dividend forecast

	Dividend per share		
	Interim	Year-end	Total
Previous forecast (fiscal year ending March 31, 2022) (Released on May 13, 2021)	8.00 yen	8.00 yen	16.00 yen
Revised forecast	—	10.00 yen	20.00 yen
Actual result for the fiscal year ending March 31, 2022	10.00 yen	—	—
Actual result for the fiscal year ended March 31, 2021	18.00 yen*	7.50 yen (Ordinary dividend 7.00 yen) (Commemorative dividend 0.50 yen)	—

Reference: After the stock split	4.50 yen	7.50 yen (Ordinary dividend 7.00 yen) (Commemorative dividend 0.50 yen)	12.00 yen (Ordinary dividend 11.50 yen) (Commemorative dividend 0.50 yen)
----------------------------------	----------	---	---

\*JCR conducted a four-for-one stock split of its common stock on October 1, 2020. Since the record date for its interim dividend is September 30, as described above, dividend per share for the six months ended September 30, 2020 represents the figure before the stock split.

### 3. Reasons

JCR regards the distribution of profits to shareholders as an important management policy. JCR's basic policy on deciding the distribution of retained earnings and related matters is to provide continuous and stable dividends in consideration of factors such as business performance and cash flows, while securing sufficient internal reserves for the development of new drug products and the strengthening of its enterprise, both of which will be sources of future profits.

As described in the news release titled "JCR Announces Revised Consolidated Financial Forecast" issued on September 30, 2021, JCR expects profits to surpass initial forecasts announced at the beginning of the fiscal year. Accordingly, JCR has decided to increase its dividends.

Based on this policy, JCR has decided to declare an interim dividend of 10.00 yen per share for the fiscal year ending March 31, 2022 (an increase of 2.00 yen from the previous forecast) and set its year-end dividend forecast at 10.00 yen per share (an increase of 2.00 yen from the previous forecast). As a result, JCR is now forecasting an annual dividend of 20.00 yen per share, an increase of 8.00 yen from the previous fiscal year.

### About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 46-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, MPS II (Hunter syndrome), acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), Hunter syndrome, Pompe disease, and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and patients. Together we soar. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

### **Cautionary Statement Regarding Forward-Looking Statements**

*This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as "believe," "estimate," "anticipate," "intend," "plan," "will," "would," "target" and similar references to future periods. All forward-looking statements regarding our plans,*

*outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors' pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions.*

*This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue.*

*Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future.*

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

[ir-info@jcrpharm.co.jp](mailto:ir-info@jcrpharm.co.jp)

###